Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices
November 14, 2013
- CSIMC OKs NHI Price Listing of 13 APIs, Takes Pass on Takeda’s OBLEAN
November 14, 2013
- Japan Govt OKs Bill to Allow Online Sales of OTC Drugs
November 14, 2013
- Expected Supplies for 4 Anti-Flu Drugs Announced for Flu Season; Tamiflu for 8 Million People
November 12, 2013
- 290 Billion Yen Invested for R&D by Drug Makers Receiving New Drug Development Premium: FPMAJ Survey
November 11, 2013
- Dr Nakagawa of JMA Says Japanese Drug Makers Should Prioritize Domestic Development
November 8, 2013
- CSIMC’s Expert Subcommittee to Present Concrete Plan on Cost-Effective Assessment by End of Year
November 8, 2013
- “Precursor Premium” Bashed by Healthcare Provider, Bill Payer Reps at CSIMC
November 7, 2013
- “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
- Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
- PAFSC’s 2nd Committee on Drugs to Review Afatinib, Brentuximab on November 18
November 7, 2013
- Lawmaker Criticizes Jikei University, Says It Should Return Government Funds
November 6, 2013
- Staff of 1,000 Eyed for PMDA by FY2018: Parliamentary Secretary
November 6, 2013
- 93 MHLW Staff Members Received 2.95 Million Yen from Novartis Pharma from 3rd Quarter of 2008 through 1st Quarter of 2013
November 6, 2013
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…